Frank Meyskens

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA
    Recent Results Cancer Res 202:115-20. 2014
  2. pmc Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial
    William B Armstrong
    Chao Family Comprehensive Cancer Center, University of California Irvine, Bldg 56, Route 81, 101 The City Drive Cancer Center, Orange, CA 92868, USA
    Cancer Prev Res (Phila) 6:410-8. 2013
  3. pmc MiTF links Erk1/2 kinase and p21 CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells
    Feng Liu
    Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA
    Mol Cancer 9:214. 2010
  4. pmc Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
    Cancer Prev Res (Phila) 4:311-23. 2011
  5. doi request reprint Thinking about the role (largely ignored) of heavy metals in cancer prevention: hexavalent chromium and melanoma as a case in point
    Frank L Meyskens
    Departments of Medicine, University of California, Irvine, USA
    Recent Results Cancer Res 188:65-74. 2011
  6. ncbi request reprint Diet and cancer: the disconnect between epidemiology and randomized clinical trials
    Frank L Meyskens
    Department of Medicine, Chao Family Comprehensive Cancer Center, Hematology Oncology, University of California, Irvine, Building 44, Route 81, 101 City Drive Cancer Center, Orange, California 92668, USA
    Cancer Epidemiol Biomarkers Prev 14:1366-9. 2005
  7. ncbi request reprint Management of human melanoma: what has the last decade wrought?
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, Orange, California 92868 3201, USA
    Oncologist 8:448-50. 2003
  8. ncbi request reprint American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the journey: the long and winding road of chemoprevention agent development
    Frank L Meyskens
    UCI Cancer center Hematology Oncology Bldg 44, Route 81 101 city Drive cancer Center CA, USA
    Cancer Epidemiol Biomarkers Prev 15:2038-41. 2006
  9. doi request reprint UV or not UV: metals are the answer
    Frank L Meyskens
    Department of Medicine and Biological Chemistry, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California 92668, USA
    Cancer Epidemiol Biomarkers Prev 17:268-70. 2008
  10. ncbi request reprint Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk
    Frank L Meyskens
    Department of Medicine, Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California
    Clin Cancer Res 10:2581-3. 2004

Research Grants

  1. Univ.of Calif., Irvine Cancer Center Support Grant
    Frank Meyskens; Fiscal Year: 2007
  2. Chemoprevention of Oral Cancer with BBIC
    Frank Meyskens; Fiscal Year: 2007
  3. Phase III Colon Cancer Prevention Trial
    Frank Meyskens; Fiscal Year: 2006
  4. Univ.of Calif., Irvine Cancer Center Support Grant
    Frank Meyskens; Fiscal Year: 2006
  5. PanAmerican Society for Pigment Cell Research (PASPCR)
    Frank Meyskens; Fiscal Year: 2004

Detail Information

Publications71

  1. doi request reprint Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA
    Recent Results Cancer Res 202:115-20. 2014
    ....
  2. pmc Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial
    William B Armstrong
    Chao Family Comprehensive Cancer Center, University of California Irvine, Bldg 56, Route 81, 101 The City Drive Cancer Center, Orange, CA 92868, USA
    Cancer Prev Res (Phila) 6:410-8. 2013
    ..This experience should be a strong cautionary note to those considering "Green" chemoprevention...
  3. pmc MiTF links Erk1/2 kinase and p21 CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells
    Feng Liu
    Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA
    Mol Cancer 9:214. 2010
    ..In addition, our data also showed that exposure to different wavelengths of UV light elicited different signal pathways involving MiTF...
  4. pmc Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
    Cancer Prev Res (Phila) 4:311-23. 2011
    ....
  5. doi request reprint Thinking about the role (largely ignored) of heavy metals in cancer prevention: hexavalent chromium and melanoma as a case in point
    Frank L Meyskens
    Departments of Medicine, University of California, Irvine, USA
    Recent Results Cancer Res 188:65-74. 2011
    ..Of interest is that aneuploidy (a universal chromosomal change in cutaneous melanoma) in lymphocytes in patients with hip-on-hip metal prostheses has been demonstrated by others...
  6. ncbi request reprint Diet and cancer: the disconnect between epidemiology and randomized clinical trials
    Frank L Meyskens
    Department of Medicine, Chao Family Comprehensive Cancer Center, Hematology Oncology, University of California, Irvine, Building 44, Route 81, 101 City Drive Cancer Center, Orange, California 92668, USA
    Cancer Epidemiol Biomarkers Prev 14:1366-9. 2005
    ..We need to be much more self-critical in the important and critical assessment of dietary compounds and their role in cancer prevention given the very high appeal for this approach both within the lay and scientific communities...
  7. ncbi request reprint Management of human melanoma: what has the last decade wrought?
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, Orange, California 92868 3201, USA
    Oncologist 8:448-50. 2003
  8. ncbi request reprint American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the journey: the long and winding road of chemoprevention agent development
    Frank L Meyskens
    UCI Cancer center Hematology Oncology Bldg 44, Route 81 101 city Drive cancer Center CA, USA
    Cancer Epidemiol Biomarkers Prev 15:2038-41. 2006
  9. doi request reprint UV or not UV: metals are the answer
    Frank L Meyskens
    Department of Medicine and Biological Chemistry, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California 92668, USA
    Cancer Epidemiol Biomarkers Prev 17:268-70. 2008
  10. ncbi request reprint Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk
    Frank L Meyskens
    Department of Medicine, Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California
    Clin Cancer Res 10:2581-3. 2004
  11. ncbi request reprint Pulling the trigger
    Frank L Meyskens
    Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA
    J Clin Oncol 22:3644-5. 2004
  12. pmc Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach
    Frank L Meyskens
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
    Cancer Prev Res (Phila) 4:628-32. 2011
    ..The pros and cons of this approach and challenges in implementing it clinically are discussed...
  13. pmc Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
    Cancer Prev Res (Phila) 1:32-8. 2008
    ..Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects...
  14. ncbi request reprint Development of difluoromethylornithine (DFMO) as a chemoprevention agent
    F L Meyskens
    Department of Medicine Hematology Oncology, and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange 92668 2675, USA
    Clin Cancer Res 5:945-51. 1999
    ..g., colon polyp recurrence) of carcinogenesis in patient populations at elevated risk for the development of specific epithelial cancers, including colon, esophageal, breast, cutaneous, and prostate malignancies...
  15. ncbi request reprint Activation of nuclear factor-kappa B in human metastatic melanomacells and the effect of oxidative stress
    F L Meyskens
    Department of Medicine and the Chao Family Comprehensive Cancer Center, University of California Irvine, Orange 92868, USA
    Clin Cancer Res 5:1197-202. 1999
    ....
  16. ncbi request reprint Criteria for implementation of large and multiagent clinical chemoprevention trials
    F L Meyskens
    Department of Medicine and Biological Chemistry, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange 92868, USA
    J Cell Biochem Suppl 34:115-20. 2000
    ..These principles will be discussed in the context of prior (CARET, ATBC) and ongoing (EUROSCAN, acetylcysteine/retinol), as well as proposed future trials (difluromethyl/sulindac)...
  17. ncbi request reprint Cancer population genetics and tumour prevention: an unfulfilled paradigm
    F L Meyskens
    Department of Medicine and Chao Family, Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA
    Eur J Cancer 36:1189-92. 2000
    ....
  18. ncbi request reprint Redox regulation in human melanocytes and melanoma
    F L Meyskens
    Department of Medicine Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange County 92868 3298, USA
    Pigment Cell Res 14:148-54. 2001
    ..This conceptual framework offers testable steps to determine the role of redox alterations in the carcinogenic evolution, prevention and treatment of melanoma and other diseases of the melanocyte...
  19. ncbi request reprint Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes
    F L Meyskens
    Department of Medicine, and Chao Family Comprehensive Cancer Center, University of California, Orange, CA 92868, USA
    Free Radic Biol Med 31:799-808. 2001
    ..g., chemotherapy). The marked enhancement of apoptosis in melanoma cells by chelators indicates, however, that this alteration can be circumvented and offers a unique therapeutic window to explore...
  20. ncbi request reprint Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer
    F L Meyskens
    Department of Medicine and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange 92868, USA
    Ann N Y Acad Sci 952:116-23. 2001
    ..Additionally, evidence for a dose-related treatment effect of BBIC on oral leukoplakia was demonstrated. These results indicate that BBIC should be investigated for chemopreventive activity in a randomized clinical trial...
  21. ncbi request reprint Principles of cancer prevention
    Frank L Meyskens
    Department of Medicine and Biological Chemistry, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92868, USA
    Semin Oncol Nurs 21:229-35. 2005
    ..To summarize the scientific principles underlying cancer prevention...
  22. ncbi request reprint Talking to a patient
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, 101 The City Drive, Route 81, Building 56, Room 210, Orange, CA 92868, USA
    J Clin Oncol 23:4463-4. 2005
  23. ncbi request reprint Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention
    F L Meyskens
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, USA
    J Natl Cancer Inst 90:1212-8. 1998
    ..In a follow-up study, we have attempted to determine the lowest dose of DFMO that can suppress the polyamine content of rectal mucosa over a course of 1 year with no or minimal side effects...
  24. ncbi request reprint Common and distinct mechanisms of different redox-active carcinogens involved in the transformation of mouse JB6P+ cells
    Sun Yang
    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92868, USA
    Mol Carcinog 47:485-91. 2008
    ..The development of the JB6P+ transformants (JB6P+/UVB; JB6P+/H(2)O(2); JB6P+/Cd) provides a unique tool to study the mechanisms that contribute to different redox-active carcinogens in a single model...
  25. ncbi request reprint Disulfiram induces apoptosis in human melanoma cells: a redox-related process
    Dazhi Cen
    Department of Medicine, Chao Family Comprehensive Cancer Center, College of Medicine, University of California, Irvine, 101 City Drive South, Building 23, Suite 403, Orange, CA 92868, USA
    Mol Cancer Ther 1:197-204. 2002
    ..Our findings have provided new data for additional understanding of drug-induced apoptosis in melanoma cells and suggests an alternative therapeutic approach to melanoma...
  26. ncbi request reprint Redox effector factor-1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells
    Sun Yang
    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California 92868, USA
    Carcinogenesis 28:2382-90. 2007
    ....
  27. ncbi request reprint Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma
    Sun Yang
    College of Medicine, University of California Irvine, 101 The City Drive South, Bldg 56, Room 215, Orange, CA 92868, USA
    Mol Pharmacol 67:298-308. 2005
    ....
  28. doi request reprint Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol
    Zhen Yang
    Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, USA
    Mol Cancer Ther 7:3751-60. 2008
    ..This phenolic antioxidant may be an appropriate choice for combining with other compounds that develop resistance by up-regulation of these molecules...
  29. doi request reprint Melanosomal damage in normal human melanocytes induced by UVB and metal uptake--a basis for the pro-oxidant state of melanoma
    Shirley Gidanian
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA
    Photochem Photobiol 84:556-64. 2008
    ..Single-dose UVB/Cu treatment does not greatly affect cell viability or cell cycle progression in heavily pigmented cells, but did so in an amelanotic early stage melanoma cell line...
  30. ncbi request reprint Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study
    David Z J Chu
    City of Hope National Medical Center, Duarte, California, USA
    Ann Surg Oncol 10:870-5. 2003
    ..Colorectal adenomas are the usual precursors to carcinoma in sporadic and hereditary colorectal cancers (CRC)...
  31. ncbi request reprint Development and characteristics of a human cell assay for screening agents for melanoma prevention
    Eugene Elmore
    Department of Radiation Oncology, University of California, Irvine, California 92697 2695, USA
    Melanoma Res 17:42-50. 2007
    ....
  32. ncbi request reprint Reactive oxygen species: a breath of life or death?
    John P Fruehauf
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92668, USA
    Clin Cancer Res 13:789-94. 2007
    ..This review will cover recent work in ROS-mediated signaling in cancer cells and its potential as a target for developmental therapeutics...
  33. ncbi request reprint New perspectives on melanoma pathogenesis and chemoprevention
    Frank L Meyskens
    University of California, Irvine, Orange 92868, USA
    Recent Results Cancer Res 174:191-5. 2007
    ..These observations offer a new paradigm for the development of preventive (and therapeutic) approaches to this disease...
  34. pmc Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas
    Christine E McLaren
    Department of Epidemiology, College of Health Sciences, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697 7550, USA
    Cancer Prev Res (Phila) 1:514-21. 2008
    ..4% (95% confidence interval, -2.0% to 18.8%; P = 0.12). There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo...
  35. pmc The effectiveness of chemoprevention agents is underestimated when lesion sizes are rounded
    Thomas H Taylor
    Genetic Epidemiology Research Institute, University of California Irvine, 92697 7550, USA
    Cancer Prev Res (Phila) 3:136-9. 2010
    ..This could easily double the required sample size for a modest phase II study. We suggest that it is cost-effective to train observers of lesion length and width to eschew rounding of measurements in the chemoprevention setting...
  36. pmc Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients
    Jason A Zell
    Chao Family Comprehensive Cancer Center, Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    J Natl Cancer Inst 102:1513-6. 2010
    ..038). Excess ototoxicity was observed among ODC1 AA patients receiving treatment, but the interaction of genotype and treatment on ototoxicity was not statistically significant (P = .45)...
  37. doi request reprint Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment
    Jason A Zell
    Division of Hematology Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine 92697, USA
    J Clin Oncol 26:66-75. 2008
    ..We set out to determine this by using the large, population-based California Cancer Registry (CCR) database as a model...
  38. pmc Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas
    Jason A Zell
    Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
    Cancer Prev Res (Phila) 2:209-12. 2009
    ..These results have implications for future NSAID-based cancer prevention clinical trials...
  39. pmc The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial
    Anne R Simoneau
    Department of Medicine, University of California, Irvine, 101 The City Drive, Route 81, Building 55, Room 304, Orange, CA 92868, USA
    Cancer Epidemiol Biomarkers Prev 17:292-9. 2008
    ..The prostate has high levels of tissue polyamines and has shown sensitivity to DFMO both in vitro and in vivo...
  40. doi request reprint MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1
    Feng Liu
    Department of Medicine, Chao Family Comprehensive Cancer Center, Irvine School of Medicine, University of California, Orange, California 92868, USA
    J Invest Dermatol 129:422-31. 2009
    ..We conclude that MiTF regulates cellular response to ROS by regulation of APE-1, and this may provide a mechanism of how MiTF is involved in melanoma carcinogenesis...
  41. ncbi request reprint End-of-Life care: guidelines for patient-centered communication
    Quyen Ngo-Metzger
    Division of General Internal Medicine and Primary Care, University of California, Irvine 92697 5800, USA
    Am Fam Physician 77:167-74. 2008
    ..Physicians also must be cognizant of how cultural factors may affect end-of-life discussions. Sensitivity to a patient's cultural and individual preferences will help the physician avoid stereotyping and making incorrect assumptions...
  42. ncbi request reprint Can a marker be a surrogate for development of cancer, and would we know it if it exists?
    William B Armstrong
    Department of Otolaryngology, University of California, Irvine, 101 The City Drive South, Bldg 25, Ste 191, Orange, CA 92868, USA
    Recent Results Cancer Res 166:99-112. 2005
    ....
  43. ncbi request reprint Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin
    Philip M Carpenter
    Department of Pathology, Irvine Medical Center, University of California, Building 10, Route 40, Room 104, 101 The City Drive South, Orange, CA 92868, USA
    Cancer Epidemiol Biomarkers Prev 13:1996-2002. 2004
    ..Following these changes during a skin cancer chemopreventative trial can then help assess the efficacy of the agent and help determine where in the progression of neoplastic changes it exerts its biological effects...
  44. ncbi request reprint Screening for cancer: valuable or not?
    Frank L Meyskens
    Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California at Irvine, 101 The City Drive, Building 56, Room 215, Route 81, Orange, CA 92868, USA
    Curr Oncol Rep 6:485-90. 2004
    ..The objective analysis for the major tumor types is presented in this review, but the ultimate decision on whether to be screened lies in the personal and societal arena of values...
  45. ncbi request reprint Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment
    William B Armstrong
    Department of Otolaryngology Head and Neck Surgery, Chao Family Comprehensive Cancer Center, University of California Irvine, 101 The City DriveSouth, Bldg 25, Suite 191, Orange, CA 92868, USA
    Laryngoscope 113:1687-702. 2003
    ....
  46. ncbi request reprint Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells
    Archana Jaiswal McEligot
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92868, USA
    Annu Rev Nutr 25:261-95. 2005
    ....
  47. ncbi request reprint Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies
    Susan E McNulty
    Department of Medicine, University of California, Irvine, Orange, CA 29868
    Pigment Cell Res 17:173-80. 2004
    ..These results confirm that the altered expression of RelA found in metastatic melanoma cells in tissue culture is relevant to human tumors and offer new insights into the deregulation of NFkappaB signaling...
  48. ncbi request reprint Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability
    Patrick J Farmer
    Department of Chemistry, University of California, Irvine, CA 92697 2025, USA
    Pigment Cell Res 16:273-9. 2003
    ..The antimelanoma effect of metal- and oxygen-induced stress appears additive rather than synergistic; both treatments are shown to be significantly less toxic to melanocytes...
  49. ncbi request reprint Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers
    William B Armstrong
    Department of Otolaryngology, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92868, USA
    Cancer Epidemiol Biomarkers Prev 12:589-92. 2003
  50. ncbi request reprint Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells
    Dazhi Cen
    Department of Medicine, University of California Irvine, Irvine, CA 92697 2025, USA
    J Med Chem 47:6914-20. 2004
    ..The implications of this work are significant both in the possible treatment of melanoma as well as in limiting the known side-effects of DSF, which we propose may be diminished by cotreatment to decrease adventitious Cu...
  51. ncbi request reprint A novel three-dimensional model to quantify metastatic melanoma invasion
    Cyrus M Ghajar
    Department of Biomedical Engineering, 3120 Natural Sciences II, University of California Irvine, Irvine, CA 92697 2715, USA
    Mol Cancer Ther 6:552-61. 2007
    ..We propose this novel, quantitative system as a useful tool to assess the effects of pharmacologic and/or microenvironmental influences on tumor cell invasion at a metastatic site...
  52. ncbi request reprint Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea
    Kenneth G Linden
    Department of Dermatology, University of California, Irvine, 101 The City Drive, Orange, CA 92868, USA
    Recent Results Cancer Res 163:165-71; discussion 264-6. 2003
    ....
  53. pmc Development of a polyamine database for assessing dietary intake
    Christine Zoumas-Morse
    Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA 92093 0901, USA
    J Am Diet Assoc 107:1024-7. 2007
    ..Development of this database linked to an FFQ provides a means of estimating polyamine intake and contributes to investigations relating polyamines to cancer...
  54. ncbi request reprint Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor
    Sun Yang
    Chao Family Comprehensive Cancer Center and Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA
    Mol Cancer Ther 4:1923-35. 2005
    ....
  55. doi request reprint Cancer prevention for global health: a report from the ASPO International Cancer Prevention Interest Group
    Dejana Braithwaite
    Department of Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94107, USA
    Cancer Epidemiol Biomarkers Prev 21:1606-10. 2012
    ..In the session presented at the ASPO 36th Annual Meeting in Washington, DC in March 2012, chaired by Drs. Frank Meyskens and Dejana Braithwaite, Dr...
  56. ncbi request reprint During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro
    Sun Yang
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA
    Pigment Cell Res 17:74-83. 2004
    ..These results suggest that components of AP-1, especially c-Jun, may offer a new target for the prevention or treatment of human melanoma progression...
  57. pmc Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma
    Sun Yang
    Chao Family Comprehensive Cancer Center, Department of Medicine, Orange, California, USA
    Antioxid Redox Signal 11:639-50. 2009
    ..Lead compounds exhibiting inhibitory effects on APE/Ref-1 are also reviewed. We anticipate potential clinical benefit in the future through inhibition of APE/Ref-1 and/or Ref-1-mediated signaling...
  58. ncbi request reprint Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Collins 5, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Cancer Res 8:314-46. 2002
    ..The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer...
  59. ncbi request reprint Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers
    Michele Follen
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2044-51. 2003
    ..Researchers recommended using a transgenic mouse model to test and validate new compounds, initiating vaccine and immunomodulator trials, and developing immunologic surrogate endpoint biomarkers...
  60. ncbi request reprint When your favorite patient relapses: physician grief and well-being in the practice of oncology
    Tait Shanafelt
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 21:2616-9. 2003
  61. ncbi request reprint Why phase II trials in cervical chemoprevention are negative: what have we learned?
    Michele Follen
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Causes Control 13:855-73. 2002
    ..SEB modulation must be characterized in any trial's earliest phases before use in phases IIb and III. Lessons learned in chemoprevention will serve as a basis for immunoprevention and vaccine trials...
  62. ncbi request reprint Polyamines and cancer: old molecules, new understanding
    Eugene W Gerner
    University of Arizona, Tucson, Arizona 85724, USA
    Nat Rev Cancer 4:781-92. 2004
    ..Clinical trials, with well-defined goals, are now underway to evaluate the chemopreventive efficacy of inhibitors of polyamine synthesis in a range of tissues...
  63. ncbi request reprint Predicting risk for the appearance of melanoma
    Frank L Meyskens
    J Clin Oncol 24:3522-3. 2006
  64. ncbi request reprint The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements
    Gary E Goodman
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Bldg M, M1 B514, Seattle, WA 98109, USA
    J Natl Cancer Inst 96:1743-50. 2004
    ....
  65. ncbi request reprint Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression
    Colin Goding
    Signalling and Development Laboratory, Marie Curie Research Institute, Surrey, UK
    Clin Cancer Res 12:1069-73. 2006
  66. ncbi request reprint An educational program to increase cervical and breast cancer screening in Hispanic women: a Southwest Oncology Group study
    Lisa K Hansen
    Columbia River CCOP, Legacy Good Samaritan Hospital, 1015 NW 22nd Avenue, W 003, Portland, OR 97210, USA
    Cancer Nurs 28:47-53. 2005
    ..Hispanic female cancer survivors can be trained as promotoras. Screening information conveyed by a promotora can successfully prompt Hispanic women to obtain mammography and Papanicolaou smears...
  67. ncbi request reprint Diet and melanoma in a case-control study
    Frank L Meyskens
    Cancer Epidemiol Biomarkers Prev 14:293. 2005
  68. ncbi request reprint Another negative chemoprevention trial: what can we learn?
    Frank L Meyskens
    Clin Cancer Res 14:2-3. 2008
  69. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  70. pmc Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study
    James C Barton
    Southern Iron Disorders Center, 2022 Brookwood Medical Center Drive, Birmingham, AL 35209, USA
    Thyroid 18:831-8. 2008
    ..We evaluated thyroid-stimulating hormone (TSH) and free thyroxine (T4) in white participants of the primary care-based Hemochromatosis and Iron Overload Screening (HEIRS) Study...
  71. ncbi request reprint Chemoprevention of FAP with sulindac
    Frank L Meyskens
    Curr Oncol Rep 4:463. 2002

Research Grants10

  1. Univ.of Calif., Irvine Cancer Center Support Grant
    Frank Meyskens; Fiscal Year: 2007
    ..Developmental funds are used to recruit faculty in areas of research the Center has identified has high priority to provide seed grants that will support collaborative translational cancer research of Center members ..
  2. Chemoprevention of Oral Cancer with BBIC
    Frank Meyskens; Fiscal Year: 2007
    ..abstract_text> ..
  3. Phase III Colon Cancer Prevention Trial
    Frank Meyskens; Fiscal Year: 2006
    ..The overall goal of our work is to develop safe combinations of chemoprevention agents that can be used in the practice setting and complement current surveillance efforts. ..
  4. Univ.of Calif., Irvine Cancer Center Support Grant
    Frank Meyskens; Fiscal Year: 2006
    ..Developmental funds are used to recruit faculty in areas of research the Center has identified has high priority to provide seed grants that will support collaborative translational cancer research of Center members...
  5. PanAmerican Society for Pigment Cell Research (PASPCR)
    Frank Meyskens; Fiscal Year: 2004
    ..abstract_text> ..